Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.37 |
| ▸ | IL1B | P01584 | 3/20 | 0.37 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31199346 | 0.92 | ADORA2A (0.43) | ADORA2AADORA1NLRP3IL1BSYK | |
| SCHEMBL31199284 | 0.91 | ADORA2A (0.40) | ADORA2AADORA1NLRP3SYKLRRK2 | |
| SCHEMBL31199342 | 0.85 | ADORA2A (0.39) | ADORA2AADORA1NLRP3IL1BSYK | |
| SCHEMBL31199546 | 0.85 | NLRP3 (0.41) | ADORA2AADORA1NLRP3IL1BSYK | |
| SCHEMBL31199751 | 0.82 | ADORA2A (0.43) | ADORA2AADORA1NLRP3IL1BSYK | |
| SCHEMBL31199314 | 0.81 | IL1B (0.45) | ADORA2AADORA1NLRP3IL1BLRRK2 | |
| SCHEMBL31199817 | 0.81 | IL1B (0.45) | ADORA2AADORA1NLRP3IL1BLRRK2 | |
| SCHEMBL31199551 | 0.80 | LRRK2 (0.37) | ADORA2AADORA1NLRP3IL1BLRRK2 | |
| SCHEMBL31199644 | 0.78 | ADORA2A (0.47) | ADORA2AADORA1SYKLRRK2PIK3CD | |
| SCHEMBL31200505 | 0.76 | ADORA2A (0.48) | ADORA2AADORA1SYKLRRK2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | claimed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | claimed |
| WO-2024188994-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-09-19 | — | — | WO | claimed |
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| WO-2024188994-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | NLRP3, NOD1, NLRP1 | ADORA2A 215/4885ADORA1 161/4885NLRP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.